# Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
Canonical URL: https://biopharmsignal.com/news/RANI/rani-therapeutics-to-present-preclinical-data-on-oral-delivery-of-semaglutide-via-the-ranipillr-capsule-at-obesityweekr-2025
Ticker: RANI
Company: Rani Therapeutics
Source: Rani Therapeutics
Published: 2025-10-30 12:01 EST
Original Source URL: http://ir.ranitherapeutics.com
## Summary

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill®

## Article Body
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill®
## Recent Company News
- 2026-07-20 20:05 EST — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) — Source: Rani Therapeutics
- 2026-07-15 12:00 EST — [Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing](https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-positive-initial-phase-1a-data-for-rt-114-for-the-tr-e7d21ddc) — Source: Rani Therapeutics
- 2026-07-09 20:05 EST — [Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates](https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-research-and-development-collaboration-with-pegbio-t-5a7630da) — Source: Rani Therapeutics
- 2026-06-29 12:00 EST — [Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer](https://biopharmsignal.com/news/RANI/rani-therapeutics-appoints-nicholas-maestas-as-chief-financial-officer-5b23c7dd) — Source: Rani Therapeutics
- 2026-05-26 12:00 EST — [Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules](https://biopharmsignal.com/news/RANI/rani-therapeutics-holdings-inc-announces-pricing-of-20-0-million-registered-direct-offering-of-class-a-common-stock-priced-at-the-market-under-nasdaq-rules) — Source: Rani Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)